Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Drug Discovery Automation: High-content Screening & Cell Based Assays

Anthony Mitchell Davies's Biography



Anthony Mitchell Davies, Director, Trinity College Dublin

Dr Davies’s research has been focused on the development of advanced in vitro c ell based models for almost 2 decades. During his early research work, Dr Davies was primarily involved in the development of specialized bioreactor cell based models utilising primary adult cardiomyocytes which were specifically designed for use in the study of the molecular events that occur during the acute and chronic phases of heart disease. Latterly Dr Davies has been active in rapidly growing field of high content screening and analysis (HCS/A) where he has been responsible for the setting up and running of one of the first purpose built academic screening centres in Europe (INCHSA) which is based in the prestigious department of Clinical Medicine Trinity College Dublin. Since its opening INCHSA has gained recognition internationally as a centre of excellence for both advanced technology development and training in the area of cell based screening. As part of these activities Dr Davies was key in the setting up and running of the first academic course specifically focused on the use of HCS/A technologies in Biomedical Research. Most recently Dr Davies has developed and commercialized a suite of novel micro-plate Bio-reactor technologies and liquid 3D cellular scaffolds specifically designed for use in automated Drug discovery.

Anthony Mitchell Davies Image

The Deployment and Evaluation of Advanced 3DTechnologies for High Content and High Throughput Screening

Thursday, 6 June 2013 at 09:00

Add to Calendar ▼2013-06-06 09:00:002013-06-06 10:00:00Europe/LondonThe Deployment and Evaluation of Advanced 3DTechnologies for High Content and High Throughput Screening SELECTBIOenquiries@selectbiosciences.com

Over the last 5 years we have been engaged in an intense research program focused on the development of novel research technologies specifically aimed at improving the biological relevance of in vitro cell based assays.  The latest addition to our technology portfolio is a completely novel cell suspension technology that has been developed to simplify the process of growing cells in 3 dimensions.


Add to Calendar ▼2013-06-06 00:00:002013-06-07 00:00:00Europe/LondonDrug Discovery Automation: High-content Screening and Cell Based AssaysSELECTBIOenquiries@selectbiosciences.com